BeiGene Ltd (BGNE) Cash Funds per Single Share

beigene.com - graphic logo of issuer BGNE

BeiGene, Ltd. (BGNE) develops high-demand oncology drugs with multi-year patent protection, ensuring stable demand. Global sales of approved medications guarantee financial strength, although clinical trial costs and US-China geopolitics pressure profits. The cash per share valuation demonstrates the business's real liquidity, where 55.36 is the current level of this metric.

BGNE BeiGene Ltd.: Cash per Single Share in the range 07/04/2022 - 11/20/2026

Analytical breakdowns for BeiGene, Ltd. (BGNE)

- market price and analyst price targets:
- cash availability and cash flow indicators:
Summary company analysis:BeiGene, Ltd. BGNE
Brand item of BeiGene Ltd

BeiGene, Ltd. (BGNE) maintains a liquidity reserve that guarantees business resilience against market volatility. Revenue growth from Brukinsa sales enables the company to effectively fund large-scale R&D projects. The current cash per share level, amounting to 55.36, reflects the actual volume of net cash per security. This metric measures the enterprise's internal resources for meeting obligations. It is critical for investors to balance protection against bankruptcy with the risk of inefficient capital allocation.

Competing companies

Cash Funds per Single Share ONC (BeiGene Corp)|Cash per Single Share HALO (Halozyme Therapeutics, Inc.)|Cash per Share Revolution Medicines, Inc. (RVMD)|Cash per Share AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cash on Hand per Share|URGN - Cash Funds per Share|Bicara Bio - Cash Calculated per Single Share|PSNL: Cash per Share|Cash Funds per Single Share ERAS|Cash per Single Share DCTH|Cash on Hand per Share Y-mAbs Therapeutics Inc YMAB|Cash per Share AURA|CADL (Candel Therapeutics, Inc.) - Amount of Cash per Share|Cash Funds per Share Accuray Inc ARAY|Cash Funds Calculated per Share SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Cash per Share|Cash on Hand per Share Citius Oncology|HURA: Cash per Share|Cash Money per Share TARA (Protara)|FATE (fatetherapeutics.com) - Cash per Share|Cash on Hand per Share Aadi Bioscience WHWK|Cash per Share TCRX|CSBR - Cash on Hand per Share|XBiotech - Cash per Single Share|CEL-SCI Corporation (CVM) - Cash on Hand per Share|OSTX - Cash Funds per Share|Cash on Hand per Share Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Cash per Single Share|ANL (Adlai Nortye Ltd) - Cash Funds per Share|Cash per Single Share VERU|Tempest Therapeutics (TPST) - Cash Funds Calculated per Share|Cash per Share XLO|Cash per Single Share Renovaro RENB|Cash per Share MURA (Mural Oncology PLC)|KAPA - Cash per Single Share|OnKure Therapeutics - Cash per Share|w2.cytomed.sg - Cash Calculated per Single Share|Curis Corp (CRIS) - Cash Funds per Share|Cash on Hand per Share Apollomics Corp (APLM)|Cash Funds per Share Tharimmune|Cash per Share advanbiomed.com|Cash Funds per Share Genprex, Inc (GNPX)|Cash Funds Calculated per Share Calidi Biotherapeutics, Inc.|Cash per Share SBFM (Sunshine Biopharma Inc.)|XBIO - Cash per Single Share|SLRX: Cash per Single Share|Amount of Cash per Share PPBT (Purple Biotech Ltd.)|AONC: Cash per Share|Checkpoint Therapeutics Inc (CKPT) - Cash per Share|ELEV (Elevation Oncology Inc.) - Cash per Share|icadmed.com (ICAD) - Cash Funds Calculated per Share|Cash per Share IKNA|NTBL (Notable Labs) - Amount of Cash per Share|Cash per Share VIRX (Viracta Therapeutics)|Cash Funds Calculated per Share MorphoSys AG (MOR)|NAYA Biosciences Corp - Cash per Share|Cash on Hand per Share ascentage.com